News

GenomeWeb – Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment

Proteomics International Laboratories announced today that it has signed an agreement to evaluate its PromarkerD test in clinical trials of Dimerix’s investigational chronic kidney disease drug DMX-200.

Article: Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment

Subscribe
  • This field is for validation purposes and should be left unchanged.